Bladder neck involvement in non‐muscle‐invasive bladder cancer: risk implications and outcomes of BCG vs gemcitabine/docetaxel
BJU International · 2025
DOI: 10.1111/bju.16827 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift BJU International, 2025. Verfasst von Ahmed Eraky und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Icahn School of Medicine at Mount Sinai Hospital, New York, NY, USA. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, BCG Vaccine, Docetaxel, Deoxycytidine. Die Arbeit nennt 29 Literaturangaben.
Abstract (Originalsprache)
Objectives
To evaluate the impact of bladder neck involvement (BNI) on oncological outcomes in non‐muscle‐invasive bladder cancer (NMIBC) and compare outcomes between Bacillus Calmette‐Guérin (BCG) and gemcitabine/docetaxel (Gem/Doce) intravesical therapies in this population. Patients and Methods We analysed consecutive patients with NMIBC who underwent transurethral resection of bladder tumour (TURBT) and received BCG or Gem/Doce from 2013 to 2023. BNI was defined as tumour presence at the bladder neck during TURBT. Recurrence‐free survival (RFS) and progression‐free survival (PFS) were assessed using Kaplan–Meier and Cox regression analyses.
Results
Among 474 patients, 58 (12%) had BNI. The median (interquartile range) follow‐up time was 34 (12–58) months. The 2‐year RFS was lower in the BNI group for any‐grade (41% vs 57%, log‐rank p = 0.003) and high‐grade recurrence (56% vs 68%, log‐rank p = 0.03). BNI independently predicted worse any‐grade RFS (hazard ratio [HR] 1.59, p = 0.02), high‐grade RFS (HR 1.68, p = 0.03), and PFS (HR 2.18, p = 0.03). While BCG and Gem/Doce had comparable 2‐year high‐grade RFS (59% vs 53%, log‐rank p = 0.31) and PFS (88% vs 68%, log‐rank p = 0.07), the multivariable analysis revealed significantly increased risk of any‐grade recurrence (HR 1.75, p < 0.001) and progression (HR 2.72, p = 0.002). Maintenance therapy improved high‐grade RFS (HR 0.43, p < 0.001) and PFS (HR 0.44, p = 0.003). Limitations include retrospective design and single‐institution data.
Conclusion
Bladder neck involvement is an independent predictor of worse outcomes in NMIBC. While unadjusted outcomes were similar, multivariable analysis showed higher recurrence and progression risk with Gem/Doce. Recognising BNI as a high‐risk factor may refine risk stratification and treatment decisions. Further studies are needed to validate these findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Icahn School of Medicine at Mount Sinai Hospital, New York, NY, USA.
ORCID-Profile: Ahmed Eraky, Reuben Ben-David, Brenda Hug, Kaushik P Kolanukuduru, Neeraja Tillu, Peter Wiklund
Zitieren
APA
Eraky, A., Ben-David, R., Hug, B., Kolanukuduru, K. P., Tillu, N., Wiklund, P., Mehrazin, R., & Sfakianos, J. P. (2025). Bladder neck involvement in non‐muscle‐invasive bladder cancer: risk implications and outcomes of BCG vs gemcitabine/docetaxel. BJU International. https://doi.org/10.1111/bju.16827
Vancouver
Eraky A, Ben-David R, Hug B, Kolanukuduru KP, Tillu N, Wiklund P, et al. Bladder neck involvement in non‐muscle‐invasive bladder cancer: risk implications and outcomes of BCG vs gemcitabine/docetaxel. BJU International. 2025. doi:10.1111/bju.16827
BibTeX
@article{Eraky2025,
author = {Eraky, Ahmed and Ben-David, Reuben and Hug, Brenda and Kolanukuduru, Kaushik P and Tillu, Neeraja and Wiklund, Peter and Mehrazin, Reza and Sfakianos, John P},
title = {Bladder neck involvement in non‐muscle‐invasive bladder cancer: risk implications and outcomes of BCG vs gemcitabine/docetaxel},
journal = {BJU International},
year = {2025},
doi = {10.1111/bju.16827}
}
EUVIMED